Clinical Trial Update: A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

This is a Phase 2 randomized trial comparing erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated locally advanced or metastatic non-small…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ARQ 197 (tivantinib)
• Tarceva (erlotinib)

Snippet

Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED